EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HSD3B1 (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers

Nikitha Vobugari iD, Allison Makovec iD, Samuel Kellen iD, Shayan S Nazari, Andrew Elliott iD, Devin Schmeck, Aiden Deacon, Gabriella von Dohlen, Emily John iD, Pedro C Barata, Neeraj Agarwal iD, Melissa A Geller iD und 8 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nikitha Vobugari und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Progesterone Reductase, Endometrial Neoplasms, Breast Neoplasms, Steroid Isomerases. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: R01, NCI NIH HHS, National Institute of General Medical Sciences, National Institutes of Health and National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HSD3B1 encodes an enzyme that catalyzes the conversion of adrenal precursors into potent sex steroids. A common germline variant (c.1100C) enhances this effect and is linked to breast cancer (BC) progression. As the HSD3B1 genotypes contribute to differences in local and adrenal steroid production, their transcriptional and phenotypic effects on cancers influenced by hormonal signaling such as BC and endometrial cancer (EC)—particularly in relation to menopausal status—remain unclear. We analyzed BC and EC sequenced from patients that received diagnostic tests in oncology clinics, and we determined the germline HSD3B1 c.1100 genotype (AA, AC, CC) from tumor DNA sequencing by using variant allele frequency, with inferred menopausal status assumed by age at molecular profiling. Whole-transcriptome RNA sequencing and gene set enrichment analysis showed that adrenal-permissive homozygous (CC) tumors in premenopausal ER + BC were enriched for hormone-related pathways, including Estrogen Response Early (NES ≈ +1.8). In premenopausal triple-negative BC, adrenal-restrictive homozygous (AA) tumors exhibited the elevated expression of immune and epithelial genes and the increased prevalence of MED12 alterations (AA 0.25% vs. CC 8%, p < 0.01). In endometrioid EC, CC tumors demonstrated the suppression of immune and proliferative pathways. Postmenopausal cases had higher progesterone receptor IHC positivity (AA 75% vs. CC 83%, p < 0.05) and numerically more frequent ESR1 copy number gains (AA 2.0% vs. CC 4.0%). Results highlight context-specific associations between germline HSD3B1 genotypes and tumor biology in BC and EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Progesterone ReductaseEndometrial NeoplasmsBreast NeoplasmsSteroid IsomerasesMultienzyme ComplexesHumansFemaleGenotypeMiddle AgedAdultAged

Stichwörter der Autor:innen

HSD3B1breast cancerendometrial cancergeneticsgenomicstranscriptomics

Substanzen

Progesterone Reductase3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomeraseSteroid IsomerasesMultienzyme Complexes

Autor:innen und Institutionen

  • Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
  • Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
  • Caris Life Sciences, Phoenix, AZ 85040, USA.
  • Department of Internal Medicine, University Hospitals Seidman Cancer Center Case Western Reserve University, Cleveland, OH 44106, USA.
  • Division of Medical Oncology, Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT 84112, USA.
  • Department of Obstetrics and Gynecology, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.

ORCID-Profile: Nikitha Vobugari, Allison Makovec, Samuel Kellen, Andrew Elliott, Emily John, Neeraj Agarwal, Melissa A Geller, Julie H Ostrander, Nima Sharifi, Justin Hwang

Förderung

  • R01
  • NCI NIH HHS
  • National Institute of General Medical Sciences, National Institutes of Health and National Cancer Institute
  • R37
  • NIH/NCI and DoD BCRP
  • P30
  • DOD grant - partial support
  • National Institute of General Medical Sciences and National Institutes of Health and National Cancer Institute

Zitieren

APA

Vobugari, N., Makovec, A., Kellen, S., Nazari, S. S., Elliott, A., Schmeck, D., Deacon, A., von Dohlen, G., John, E., Barata, P. C., Agarwal, N., Geller, M. A., Erickson, B. K., Sledge, G., Ostrander, J. H., McKay, R. R., Ryan, C. J., Sharifi, N., Antonarakis, E. S., & Hwang, J. (2025). HSD3B1 (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125720

Vancouver

Vobugari N, Makovec A, Kellen S, Nazari SS, Elliott A, Schmeck D, et al. HSD3B1 (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125720

BibTeX
@article{Vobugari2025,
  author = {Vobugari, Nikitha and Makovec, Allison and Kellen, Samuel and Nazari, Shayan S and Elliott, Andrew and Schmeck, Devin and Deacon, Aiden and von Dohlen, Gabriella and John, Emily and Barata, Pedro C and Agarwal, Neeraj and Geller, Melissa A and Erickson, Britt K and Sledge, George and Ostrander, Julie H and McKay, Rana R and Ryan, Charles J and Sharifi, Nima and Antonarakis, Emmanuel S and Hwang, Justin},
  title = {HSD3B1 (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125720}
}
Kostenlos starten →